STOCK TITAN
  1. Home
  2. Sec-filings
  3. EW
  4. [Form 4] Edwards Lifesciences Corp Insider Trading Activity

EW insider sells 1,020 shares after option exercise under 10b5-1

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences (EW) reported an insider Form 4 for an officer (CVP, JAPAC) on 11/10/2025. The reporting person exercised 1,020 employee stock options at $59.2567 and sold 1,020 common shares at a weighted average price of $82.5451, with trades ranging from $82.27 to $82.90. These transactions were made under a Rule 10b5-1 trading plan adopted on July 30, 2025. After the transactions, direct ownership was 22,001.9103 shares, and 6,114 derivative securities remained held directly.

Positive

  • None.

Negative

  • None.
Insider Lippis Daniel J.
Role CVP, JAPAC
Sold 1,020 shs ($84K)
Type Security Shares Price Value
Exercise Employee Stock Option (Right to Acquire) 1,020 $0.00 --
Exercise Common Stock 1,020 $59.2567 $60K
Sale Common Stock 1,020 $82.5451 $84K
Holdings After Transaction: Employee Stock Option (Right to Acquire) — 6,114 shares (Direct); Common Stock — 23,021.91 shares (Direct)
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. This transaction was executed in multiple trades at prices ranging from $82.27 to $82.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lippis Daniel J.
(Last) (First) (Middle)
ONE EDWARDS WAY
(Street)
IRVINE CA 92614
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CVP, JAPAC
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/10/2025 M(1) 1,020 A $59.2567 23,021.9103 D
Common Stock 11/10/2025 S(1) 1,020 D $82.5451(2) 22,001.9103 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Acquire) $59.2567 11/10/2025 M 1,020 05/08/2020 05/07/2026 Common Stock 1,020 $0.0000 6,114 D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
2. This transaction was executed in multiple trades at prices ranging from $82.27 to $82.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact 11/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did EW report on Form 4?

An officer exercised 1,020 stock options at $59.2567 and sold 1,020 shares at a $82.5451 weighted average price.

Was the EW insider trade under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 plan adopted on July 30, 2025.

What sale prices were reported for EW shares?

Sales occurred in multiple trades from $82.27 to $82.90; the weighted average price was $82.5451.

How many EW shares and derivatives does the insider hold after?

Direct ownership is 22,001.9103 shares and 6,114 derivative securities remained held directly.

What were the option terms tied to the EW exercise?

The option had an exercise price of $59.2567, covered 1,020 shares, became exercisable on 05/08/2020, and expires on 05/07/2026.

Who is the reporting person’s role at EW?

The reporting person is an Officer with the title CVP, JAPAC.